In 153 previously treated adults with radioiodine-refractory BRAFV600E-positive differentiated thyroid cancer, dabrafenib plus trametinib extended median PFS vs placebo (12·8 vs 3·7 months; HR 0·38). Interim OS not significant; serious adverse events 43% vs 25%.
RCTn = 153
Gao et al. Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial